Evidence map›Paper›PMID 42771310›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Production of Lentiviral Vectors Encoding the CRISPR-Cas13d System for RNA Targeting.

Roberta Stilhano, Leonardo Martin

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Roberta StilhanoDepartment of Physiological Sciences, Santa Casa de São Paulo School of Medical Sciences, 61 Dr Cesário Mota Junior Street, São Paulo, SP, Brazil.
Leonardo MartinDepartment of Pharmaceutical Sciences, Laboratory of Physiopharmacology, University of Antwerp, Universiteitsplein 1, Campus Drie Eiken, D.T.231, Antwerp, Belgium. leonardo.martin@uantwerpen.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CRISPR-Cas13d system has been shown to be a potent tool for target RNA knockdown, offering advantages over DNA-editing systems by providing a non-genotoxic method to modulate gene expression. Efficient delivery of Cas13d and its guide RNAs into target cells is essential to achieve a strong knockdown effect, particularly in cell lines that are difficult to transfect and primary cells. Lentiviral vectors (LVs) are ideal for delivering large gene-editing tools due to their large packaging capacity and ability to transduce both dividing and nondividing cells. Here, we describe a detailed protocol for the production of high-titer, third-generation LVs with a dual-expression cassette for Cas13d and a customizable guide RNA. The method describes the cloning of target-specific guide RNAs, the transfection of HEK293T cells with packaging and transfer plasmids, the harvest and concentration of viral supernatants, and the determination of viral titer. The generated lentiviral particles can be used for stable transduction and efficient RNA knockdown in a broad range of mammalian cell types.

Indexed as

CRISPR-Cas SystemsGene EditingGenetic VectorsLentivirusGene Knockdown TechniquesHEK293 CellsHumansPlasmidsRNA, Guide, CRISPR-Cas SystemsTransduction, GeneticTransfectionRNA, Guide, CRISPR-Cas SystemsCRISPR–Cas13dGuide RNA cloningLentivirusRNA knockdownViral production

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.